Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-06-14
2011-06-14
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S328000
Reexamination Certificate
active
07960348
ABSTRACT:
The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotropic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc.
REFERENCES:
patent: 6699965 (2004-03-01), Watanabe et al.
patent: 7725869 (2010-05-01), Kitada et al.
patent: 7754220 (2010-07-01), Ohtaki et al.
patent: 2003/0096956 (2003-05-01), Suenaga et al.
patent: 2004/0185525 (2004-09-01), Nishimura et al.
patent: 2004/0236077 (2004-11-01), Matsumoto et al.
patent: 2005/0176091 (2005-08-01), Yamada et al.
patent: 2005/0240008 (2005-10-01), Ohtaki et al.
patent: 2006/0241051 (2006-10-01), Kitada et al.
patent: 2006/0287227 (2006-12-01), Ohtaki et al.
patent: 2009/0093615 (2009-04-01), Asami et al.
patent: 2009/0099334 (2009-04-01), Asami et al.
patent: 2009/0105152 (2009-04-01), Asami et al.
patent: 0162575 (1985-11-01), None
patent: 0472220 (1992-02-01), None
patent: 1126028 (2001-08-01), None
patent: 1577323 (2005-09-01), None
patent: 1604682 (2005-12-01), None
patent: 9-169735 (1997-06-01), None
patent: 2002-320496 (2002-11-01), None
patent: 2003-26601 (2003-01-01), None
patent: 2003300906 (2003-10-01), None
patent: 2004217651 (2004-08-01), None
patent: 2002102081 (2003-09-01), None
patent: 2005135739 (2006-03-01), None
patent: 2306147 (2007-09-01), None
patent: 2311920 (2007-12-01), None
patent: 2006/145886 (2008-06-01), None
patent: 2333221 (2008-09-01), None
patent: 2344831 (2009-01-01), None
patent: 2008125063 (2009-12-01), None
patent: WO-97/14682 (1997-04-01), None
patent: WO-97/40071 (1997-10-01), None
patent: WO-98/39448 (1998-09-01), None
patent: WO-00/24890 (2000-05-01), None
patent: 0100228 (2001-01-01), None
patent: 019286 (2001-02-01), None
patent: WO-01/44469 (2001-06-01), None
patent: 0172295 (2001-10-01), None
patent: WO-01/74377 (2001-10-01), None
patent: WO-01/75104 (2001-10-01), None
patent: WO-02/085399 (2002-10-01), None
patent: WO-02/092829 (2002-11-01), None
patent: WO-03/027149 (2003-04-01), None
patent: WO-03/060125 (2003-07-01), None
patent: WO-2004/038021 (2004-05-01), None
patent: WO-2004/060264 (2004-07-01), None
patent: WO-2004/063221 (2004-07-01), None
patent: 2004073730 (2004-09-01), None
patent: WO-2004/080479 (2004-09-01), None
patent: WO-2004/087622 (2004-10-01), None
patent: 2004093894 (2004-11-01), None
patent: WO-2004/096855 (2004-11-01), None
patent: WO-2004/101747 (2004-11-01), None
patent: WO-2004/106289 (2004-12-01), None
patent: 2005042744 (2005-05-01), None
patent: WO-2005/095973 (2005-10-01), None
patent: WO-2006/001499 (2006-01-01), None
patent: WO-2007/072997 (2007-06-01), None
patent: WO-2007/084211 (2007-07-01), None
patent: 2008050897 (2008-05-01), None
Search Report with English translation form corresponding Georgian Patent Application No. AP 2006 010770 issued on Nov. 30, 2009.
Niida et al., “Design and synthesis of downsized metastin (45-54) analogs with maintenance of high GPR54 agonistic activity,” Bioorganic & Medicinal Chemistry Letters (2006) 16:134-137.
Tomita et al., “Structure-activity relationship study on small peptidic GPR54 agonists,” Bioorganic & Medicinal Chemistry (2006) 14:7595-7603.
Venkatesan et al., “Synthesis and Enzyme Inhibitory Activities of Novel Peptide Isosteres,” Current Medicinal Chemistry (2002) 9:2242-2270.
Search Report of Corresponding Georgian Patent Application No. 2005 010294, Issued on Dec. 8, 2008.
Official Action of Corresponding Japanese Patent Application No. 2008-245073, Issued on Mar. 31, 2009.
Dutta et al., “Polypeptides. Part 15. Synthesis and Biological Acitvity of α-Aza-analogues of Luliberin modified in Positions 6 and 10,” J. Chemical Society, Perkin Transactions (1979) vol. 1, No. 2, pp. 379-388.
Ohtaki et al., “Metastasis suppressor geneKiSS-1 encodes peptide ligand of a G-protein-coupled receptor,” Nature (2001), vol. 411, pp. 613-617.
Kotani et al., “The Metastasis Suppressor GeneKiSSEncodes Kisspeptins, the Natural Ligands of the Orphan G Protein-coupled Receptor GPR54,” J. of Biol. Chem. (2001), vol. 276, pp. 34631-34636.
Ringel et al., “Metastin Receptor is Overexpressed in Papillary Thyroid Cancer and Activates MAP Kinase in Thyroid Cancer Cells,” J. of Clin. Endocrinology & Metabolism (2002), vol. 87, pp. 2399-2402.
Han et al., “Orphan G protein-coupled receptors MrgA1 and MrgC11 are distinctively activated by RF-amide-related peptides through the Gαq/11pathway,” Proc. Natl. Acad. Sci. USA (2002), vol. 99, pp. 14740-14745.
Horikoshi et al., “Dramatic Elevation of Plasma Metastin Concentrations in Human Pregnancy: Metastin as a Novel Placenta-Derived Hormone in Humans,” J. of Clin. Endocrinology & Metabolism (2003), vol. 88, pp. 914-919.
53rd, Nihon Yakugaku Kai, Kinki Shibu Sokai, Taikai Koen Yoshi-shu (2003) Yuki 2B-13-2 (Japanese language, translation enclosed).
Masui et al., “Metastin and its variant forms suppress migration of pancreatic cancer cells,” BBRC (2004), vol. 315, pp. 85-92.
Terao et al., “Expression ofKiSS-1, a metastasis suppressor gene in trophoblast giant cells of the rat placenta,” Biochimica et Biophysica Acta (2004), vol. 1678, pp. 102-110.
Gottsch et al., “A Role for Kisspeptins in the Regulation of Gonadotropin Secretion in the Mouse,” Endocrinology (2004), vol. 145, pp. 4073-4077.
S. Hinuma et al., “A prolactin-releasing peptide in the brain”, Nature, vol. 393, pp. 272-276 (1998).
J.C. Meunier et al. “Molecular Neuroendocrinology: Working backwards to find answers”, Nature, vol. 393, pp. 211-212 (1998).
H. Satake et al., “Characterization of a cDNA encoding a novel avian hypothalamic neuropepetide exerting an inhibitory effect on gonadotropin release”, Biochem. J., vol. 354, pp. 379-385 (2001).
Muir et al., “AXOR12, a Novel Human G Protein-coupled Receptor, Activated by the PeptideKiSS-1,” Journal of Biological Chemistry (2001), 276(31):28969-28975.
Supplementary European Search Report for corresponding European application EP04719659, dated May 26, 2009.
EPO Form 1507N, Jun. 10, 2010, European Search Report for EP 09075257.7.
Bruehlmeier M, et al, Nuclear Medicine and Biology, vol. 29, No. 3, Apr. 1, 2002, pp. 321-327.
Cudic M, et al, Peptides, Elsevier, vol. 23, Jan. 1, 2002, pp. 2071-2083.
Georgian Srch Rpt, Nov. 16, 2010, Srch Rpt for Georgian patent appln AP2007011265.
Asami Taiji
Nishizawa Naoki
Conlin, Esq. David G.
Edwards Angell Palmer & & Dodge LLP
Kosar Andrew D
Lauro, Esq. Peter C.
Takeda Pharmaceutical Company Limited
LandOfFree
Metastin derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metastin derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metastin derivatives and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2649711